Eli Lilly tees up discovery pact worth more than $1.6B with Merus for T cell-focused bispecific antibodies

Kyle Blankenship

Under science chief Dan Skovronsky, Eli Lilly has taken some big swings at next-gen therapies, including trying to find the next big thing in oncology …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Eli Lilly tees up discovery pact worth more than $1.6B with Merus for T cell-focused bispecific antibodies

Kyle Blankenship

Sign up to read this article for free.

Post-Hoc: RFK vs. Vivek, and the future of US drug policy

Evotec gains on Halozyme's takeover proposal

Boston Pharmaceuticals hits Phase 2 goals as it tries to keep up with MASH competitors

Adaptimmune to 'redefine' itself as a sarcoma biotech, cuts a third of staffers

European drug regulators offer wave of positive recommendations following Leqembi reversal

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

Eli Lil­ly tees up dis­cov­ery pact worth more than $1.6B with Merus for T cell-fo­cused bis­pe­cif­ic an­ti­bod­ies

Kyle Blankenship

Sign up to read this article for free.

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

Evotec gains on Halozyme's takeover pro­pos­al

Boston Phar­ma­ceu­ti­cals hits Phase 2 goals as it tries to keep up with MASH com­peti­tors

Adap­ti­m­mune to 're­de­fine' it­self as a sar­co­ma biotech, cuts a third of staffers

Eu­ro­pean drug reg­u­la­tors of­fer wave of pos­i­tive rec­om­men­da­tions fol­low­ing Leqem­bi re­ver­sal

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

Eli Lilly tees up discovery pact worth more than $1.6B with Merus for T cell-focused bispecific antibodies

Post-Hoc: RFK vs. Vivek, and the future of US drug policy

Evotec gains on Halozyme's takeover proposal

Boston Pharmaceuticals hits Phase 2 goals as it tries to keep up with MASH competitors

Adaptimmune to 'redefine' itself as a sarcoma biotech, cuts a third of staffers

European drug regulators offer wave of positive recommendations following Leqembi reversal

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?